top of page

Blog

Clare Koning pic.jpg

Blog Author: Clare Koning

Clare is a freelance healthcare writer and registered nurse with over 20 years of international experience. She specializes in evidence-based health communications and currently leads digital content strategy and development for the T2D Network.

Written by Clare Koning, RN, PhD Clare Koning, RN, PhD is a senior medical writer and healthcare communications consultant with 20+ years of international experience across nursing leadership, clinical operations, and scientific publications. She specializes in translating complex clinical and scientific data into clear, high-impact content for healthcare professionals and patients.

Type 2 Diabetes in 2026: A Year in Review

Writer: T2D Network
T2D Network
Oct 28
8 min read

Updated: 2 days ago

Written by Clare Koning, RN, PhD - 7 min read


Key Highlights

✅ 2026 was the most consequential year in T2D pharmacology

✅ The 2026 ADA Standards of Care expanded CGM recommendations

✅ The T2D Network published more than 35 evidence-based blog posts

✅ The IDF’s “Early Action on Diabetes” campaign set the agenda for 2026/2027


December arrives with the particular quality of light that makes the year feel conclusively behind you. In diabetes care and research, 2026 did not go gently. It was a year of genuine scientific momentum, hard clinical questions, updated guidelines, and, above all, a growing insistence in the research and advocacy communities that the standard of care for people living with type 2 diabetes must be better, more equitable, more whole-person, and more honest than it has historically been.


2026

Here at the T2D Network, we spent 2026 trying to meet that insistence with content that reflects it: evidence-based, clinically grounded, and written for real people navigating a condition that never takes a day off.


This is our look back at the year that was, and our look forward at what 2027 may bring.


The Research Story of 2026


The Oral GLP-1 Era Began


On April 1, 2026, the FDA approved orforglipron (Foundayo; Eli Lilly), making it the first non-peptide oral GLP-1 receptor agonist in history to receive regulatory approval. Approved initially for obesity and overweight with weight-related medical conditions, it marked a genuine structural shift in how GLP-1 therapy can be delivered.


What makes orforglipron different from existing oral semaglutide (Rybelsus) is its chemistry. As a small molecule rather than a peptide, it does not break down in the gut the same way and can be taken once daily at any time, without the 30-minute fasting restriction that limits real-world adherence to oral semaglutide. Patients in trials lost 12% to 15% of their body weight. In the ACHIEVE-3 head-to-head trial, orforglipron demonstrated greater A1C reduction than oral semaglutide in people with type 2 diabetes (2.2% versus 1.4%).


A type 2 diabetes NDA submission to the FDA was planned for mid-2026, with a decision anticipated by late 2026 or early 2027. For Canadians living with T2D who cannot tolerate or do not want injections, this pipeline development has been one of the most anticipated of the year. We covered the full picture, including the caveats around gastrointestinal side effects and the fact that the T2D indication is not yet approved, in our oral GLP-1 blog earlier this year.


2026 was the year a daily diabetes pill without needles, without fasting, and without refrigeration moved from clinical trial to pharmacy shelf. The era of accessible oral GLP-1 therapy has begun.

The Triple Agonist Arrived in Phase 3


If orforglipron was the year’s approval story, retatrutide was its clinical trial story.

In March 2026, Eli Lilly announced positive top-line results from TRANSCEND-T2D-1, the first Phase 3 trial of retatrutide in type 2 diabetes. The drug targets three hormonal receptors simultaneously: GLP-1, GIP, and glucagon, producing combined effects on appetite suppression, glycemic control, and energy expenditure that neither dual nor single agonists match.


The results presented at the ADA 2026 Scientific Sessions in New Orleans in June were striking: up to 2% A1C reduction and a mean weight loss of 36.6 pounds over approximately 40 weeks in people with early-onset T2D. The study’s lead author, Canadian endocrinologist Dr. Harpreet Singh Bajaj of LMC Diabetes and Endocrinology, described the magnitude of weight loss as having “the potential to slow disease progression and reshape how we treat and manage type 2 diabetes.”


Longer-term Phase 3 trials are now underway, including a head-to-head comparison of retatrutide versus semaglutide (TRANSCEND-T2D-2) over 80 weeks. Regulatory submission is expected in 2027.


laboratory

The January 2026 Metabolomics Landmark


Before the clinical trial results dominated headlines, January brought a different kind of scientific milestone. Researchers from Mass General Brigham and Albert Einstein College of Medicine published a study in Nature Medicine identifying a 44-metabolite blood signature capable of predicting T2D risk up to 26 years before diagnosis, across 23,634 participants in 10 prospective cohorts. The study also found that diet and lifestyle factors had a stronger influence on the diabetes-linked metabolites than on other metabolites, reinforcing what we already know: the biology of T2D is shaped by choices made years before any clinical threshold is crossed.


It is not yet a clinical test. But it is a scientific milestone that is quietly reshaping how researchers think about early intervention windows.


The 2026 ADA Standards of Care


Each January, the ADA releases updated clinical guidelines. The 2026 Standards of Care made several changes that directly affect people with T2D.


CGM was formally recommended from the time of T2D diagnosis for all who could benefit, not just those on insulin. Blood pressure targets were tightened for high-cardiovascular-risk patients following the ESPRIT trial’s 21% reduction in major cardiac events with intensive management. Updated guidance on GLP-1 effects on retinopathy acknowledged the early worsening signal in people with pre-existing eye disease starting rapid glycemic treatment. And for the first time, diabetes stigma and discrimination were formally addressed in the Standards, acknowledging that what happens in the consulting room affects what happens to blood sugar.


The Mindfulness Meta-Analysis That Surprised Us


Published in Integrative Medicine Research in March 2025 and drawing significant clinical attention through 2026, the most comprehensive systematic review and meta-analysis of mindfulness-based interventions in T2D to date confirmed that MBIs reduce depression symptoms (SMD -1.26), stress (SMD -1.01), and anxiety (SMD -0.67) in people with T2D, alongside a mean HbA1c reduction of 0.44% across nine trials. The certainty of evidence remains low to very low. But the direction is consistent, and the signal that psychological wellbeing and glycemic control are not separate conversations continued to strengthen throughout the year.


What the T2D Network Did in 2026


In 2026, the T2D Network continued to support and promote diabetes screening clinics across Canada, connecting Canadians with free or low-cost blood sugar testing, risk assessments, and access to registered diabetes educators in their communities. Screening clinics remain one of the most direct ways to close the diagnosis gap that sits at the heart of this year’s World Diabetes Day theme: finding the people who do not yet know they have T2D, before complications find them first.


T2D screening

This year, we committed to publishing evidence-based content that takes the full picture of living with type 2 diabetes seriously, not just the blood sugar numbers, but the mental load, the social dimensions, the body signals people miss, the misinformation flooding social media feeds, and the research findings that genuinely change what is possible.

Some of the ground we covered this year, grounded in recent peer-reviewed evidence and linked throughout:


We wrote about the signs of T2D that are easy to miss, including skin changes, slow-healing wounds, and neuropathy symptoms that appear years before a formal diagnosis. That post became one of our highest-traffic of the year, and it told us something important about what Canadians are looking for: not just information about managing diabetes, but information that helps them recognize it in the first place.


We wrote about diabetes burnout, because the IDF’s finding that 79% of people with diabetes experience burnout and 3 in 4 have interrupted treatment as a result deserves to be named, not whispered around.



We wrote about the people who are being underserved by standard diabetes screening protocols: young adults under 40, new diganosis T2D and what to do, women navigating menopause, and the new Pharmacare coverage in British Columbia.


And in the spirit of this year’s World Diabetes Day theme, Early Action on Diabetes, we wrote consistently about the window that exists before diagnosis, when lifestyle, awareness, and a simple blood test can still change the trajectory completely.

The T2D Network’s Learn More, Healthy Eating, Healthy Lifestyle, and Monitoring & Medication pages continued to serve as practical anchor points for Canadians at every stage of their diabetes journey.


What to Watch in 2027


Orforglipron’s T2D Approval Decision


The FDA’s decision on orforglipron for type 2 diabetes is anticipated in late 2026 or early 2027, with Health Canada review timelines typically following US approvals. If approved for T2D, it will become the first truly unrestricted oral GLP-1 option for the diabetes indication, potentially transforming access for the significant proportion of people with T2D who are not on insulin and who have been reluctant to start injectable therapy.


Retatrutide’s Long-Term Data


The TRANSCEND-T2D-2 and TRIUMPH-2 trials, comparing retatrutide against semaglutide in people with T2D over 80 weeks and in people with T2D and obesity respectively, are expected to report in 2027. These head-to-head results will be the most important data in the triple agonist story, moving beyond placebo comparisons to the question that actually matters clinically: how much better is the triple agonist, and for whom?


CagriSema’s Anticipated Approval


CagriSema, Novo Nordisk’s once-weekly combination of semaglutide and the long-acting amylin analogue cagrilintide, is expected to receive FDA approval by late 2026 or early 2027. Early data show clinically relevant improvements in weight and glycemic control that go beyond semaglutide alone. If approved, it will be the first combination incretin-amylin agent on the market, adding another tool to the rapidly expanding metabolic therapy landscape.


AI in Diabetes Screening and Management


At the EASD 2026 conference in September, researchers reported that a 20-second voice recording could identify people at increased risk of T2D with 80% accuracy. AI-based retinal imaging for diabetic retinopathy screening, already validated and beginning to deploy in primary care settings, will expand further in 2027. These tools carry significant potential for equity: reaching people in communities underserved by specialist ophthalmology or endocrinology through the primary care and community settings they do access.


robot

The Metabolomics Clinical Path


The metabolomic risk signature described in the January 2026 Nature Medicine study will move closer to clinical validation in 2027 as further cohort studies test its predictive accuracy in diverse populations. The prospect of a blood test that flags T2D risk a decade before standard clinical markers shift represents a paradigm shift in preventive medicine that could, if validated and made accessible, fundamentally change who gets screened and when.


Personalised Nutrition and CGM Data


The convergence of CGM real-time data, gut microbiome profiling, and machine learning algorithms to generate truly personalised dietary recommendations for people with T2D is a field that several research groups are advancing actively. The expectation by many researchers is that by the end of the decade, “what should I eat for my diabetes” will have a meaningfully different and more individual answer than the population-level guidance we currently offer.


A Word for December


December is the month when people take stock. It is also the month most likely to bring disrupted routines, more social eating, fewer daylight hours, and the kind of low-grade seasonal stress that, as we covered this year, has real effects on cortisol and blood sugar.

If you are living with T2D, the end of the year is not an invitation to abandon the habits that are working. It is an invitation to be gentle with yourself when they are harder to maintain, and to remember that consistency over weeks and months matters far more than any single holiday meal or skipped gym session.


If you are not yet diagnosed but have been noticing signs, or have a family member whose risk has been on your mind, January is statistically one of the most common months for people to book health appointments they have been putting off. Consider this your reminder to make one.


And if 2026 was a year in which your diabetes felt like more than you could carry at times, that experience is documented, named, and widely shared. You are not alone in it. And 2027 has more options, more research, and more recognition of the full weight of what you are managing than the year before it.


That is, quietly, progress.


The T2D Network publishes evidence-based content for Canadians living with and at risk of type 2 diabetes. Visit our Learn More page, explore our Healthy Eating and Healthy Lifestyle pages, and find your nearest Diabetes Education Centre. Take the CANRISK questionnaire to check your personal risk.


From everyone at the T2D Network: thank you for reading, sharing, and trusting us with your time this year.


bottom of page